Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, November 18, 2016
U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early Alzheimer's Disease
Friday, November 4, 2016
U.K. NICE Recommends Anticancer Agent Halaven as Treatment for Advanced Breast Cancer
Monday, October 31, 2016
Enrollment Commences in Phase III Clinical Study of Eisai's BACE Inhibitor E2609 in Early Alzheimer's Disease
Thursday, October 13, 2016
Eisai to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide
Wednesday, October 12, 2016
Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016
Tuesday, October 4, 2016
Exclusive Licensing Agreement for In-house Developed Monoclonal Antibody Farletuzumab in Latin America Concluded with Eurofarma Laboratorios S.A.
Launch of Uritos Tablets for Overactive Bladder in Thailand
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States
Friday, September 30, 2016
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma
Thursday, September 29, 2016
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: